Article Text

Download PDFPDF

5PSQ-054 Endophthalmitis after intravitreal injection with anti-angiogenic drugs: a rare but serious complication
  1. C Aparicio Carreño,
  2. A Gándara Ande,
  3. A Fórneas Sangil,
  4. B Fernández González,
  5. A Ayastuy Ruiz,
  6. R Pampín Sánchez,
  7. C Martínez-Múgica Barbosa,
  8. A Fernández González
  1. Hospital Universitario de Cabueñes, Hospital Pharmacist, Gijón, Spain


Background and importance Endophthalmitis is a serious complication, which is becoming more frequent due to population ageing and the steady increase of intravitreal injections with anti-angiogenic drugs (IAD).

Aim and objectives To analyse the incidence of endophthalmitis in patients who received IAD, to describe the population affected and to classify endophthalmitis.

Material and methods A retrospective observational study was conducted from January 2017 to December 2020. Patients who received any IAD (aflibercept or ranibizumab) and developed endophthalmitis were included.

Aflibercept was preloaded in syringes in a safety cabinet (SC) while ranibizumab was ready to use. IAD was performed in a ‘clean room’, 5% povidone iodine or 0.05% chlorhexidine eye drops (in patients allergic to iodine) prepared in a SC by the Pharmacy Service were administered in the conjunctival sac, a blepharostat was placed and the drug was administered. Antibiotic eye drops were recommended according to the ‘Spanish Vitreo-Retinal Society’.

Patients who developed endophthalmitis were admitted to hospital. Cultures were taken, intravitreal, topical and/or systemic antibiotic treatment was administered. The need for vitrectomy was assessed individually, requiring follow-up until resolution.

Endophthalmitis was classified by: (1) time: acute (less than 6 weeks since the procedure) or chronic (more than 6 weeks), (2) aetiology: infectious (positive culture) or non-infectious (negative culture) and (3) severity: good or bad prognosis (according to clinical criteria).

Results 12 057 IAD (7765 aflibercept, 4292 ranibizumab) were administered and 7 endophthalmitis (incidence 0.058%) were recorded, always after using aflibercept.

All cases were acute (always within 10 days after last IAD), 4 infectious (3 with Staphylococcus epidermidis and 1 with Micrococcus luteus) and 3 non-infectious. One case (14%) ended up with a bad prognosis.

Mean age was 63 (46–85) years, 4 males and 3 females. The average length of stay in hospital was 12 (7–21) days. Vitrectomy was performed in 4 patients. Average number of IAD received until development of endophtalmitis was 5 (2–11); 6 patients (85%) developed it after 3 or more IAD.

Conclusion and relevance Endophthalmitis after IAD is an acute, usually infectious, potentially hazardous and infrequent complication (0.019%–0.58%, incidence rate similar to previously reported). It always occurred with aflibercept, so drug handling, even under sterile conditions, might be a risk factor.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.